HSD3B1 (1245A>C) germline variant and clinical outcomes in metastatic castration-resistant prostate cancer patients treated with abiraterone and enzalutamide: results from two prospective studies
Titel:
HSD3B1 (1245A>C) germline variant and clinical outcomes in metastatic castration-resistant prostate cancer patients treated with abiraterone and enzalutamide: results from two prospective studies
Auteur:
Khalaf, D.J. Aragón, I.M. Annala, M. Lozano, R. Taavitsainen, S. Lorente, D. Finch, D.L. Romero-Laorden, N. Vergidis, J. Cendón, Y. Oja, C. Pacheco, M.I. Zulfiqar, M. Gleave, M.E. Wyatt, A.W. Olmos, D. Chi, K.N. Castro, E.